Our findings highlight several particularly promising therapeutic targets: the STAT3 signaling axis, which showed consistent dysregulation across multiple analytical modalities and central positioning in inflammatory networks; the PI3K/AKT pathway, which emerged as a critical hub in our network analysis with strong connections to both metabolism and inflammatory signaling; and specific kinases in the DYRK, GSK, and MAPK families that demonstrated altered activity in our kinomic analysis and have been previously implicated in neuroinflammatory processes in AD. Here, DYRK1A is linked to Alzheimer disease.